Pharmaceuticals Company Research Reports

Pharmaceuticals companies are involved into development, production as well as marketing of an extensive variety of medicines. The pharmaceuticals industry is represented by innumerable companies. Small biotechnology and biopharmaceutical manufacturers, mid-sized specialty companies, large multi-nationals enterprises are amid the world pharma companies.

Appearance of new products; introduction of new product costs structures and modes of healthcare delivery; modification of product cost, offerings and design; growing public scrutiny; scientific researches in the fields of nanotechnology, bioengineering, etc. are among trends contributing to changes in the pharmaceutical industry.

Johnson & Johnson, Pfizer, Inc., Roche Holding AG, Novartis International AG, Abbott Laboratories, etc. are amid behemoths of the pharmaceutical industry.

Within this MarketPublishers’ catalogue there are innumerable reports featuring pharmaceutical companies’ overviews. The research reports provide a state-of-the-art picture of the pharma market including the analyses of the pharmaceuticals companies. Evaluation of companies’ strategies and data on products offerings are available in the research studies.

Found 5955 publications
Wroclawskie Centrum Badan EIT+ Sp. z o.o. - Product Pipeline Review - 2014 US$ 1,500.00

... action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Wroclawskie Centrum Badan EIT+ Sp. z o.o.’s pipeline products ...

Mar, 2014 16 pages
Visceral Pain - Pipeline Review, H1 2014 US$ 2,000.00

Summary Global Markets Direct’s, ‘Visceral Pain - Pipeline Review, H1 2014’, provides an overview of the Visceral Pain’s therapeutic pipeline. This report provides ... type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for ...

Mar, 2014 41 pages
Serendex Pharmaceuticals A/S - Product Pipeline Review - 2014 US$ 1,500.00

... action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Serendex Pharmaceuticals A/S’s pipeline products ...

Mar, 2014 23 pages
Orphazyme ApS - Product Pipeline Review - 2014 US$ 1,500.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Orphazyme ApS’s pipeline products ... drug targets and therapeutic classes in the Orphazyme ApS’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Mar, 2014 25 pages
Natco Pharma Limited - Product Pipeline Review - 2014 US$ 1,500.00

... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Natco Pharma Limited’s pipeline products Reasons ... of focus Identify new drug targets and therapeutic classes in the Natco Pharma Limited’s R&D portfolio and develop key strategic initiatives to reinforce ...

Mar, 2014 27 pages
ImmunGene, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the ImmunGene, Inc.’s pipeline products ... drug targets and therapeutic classes in the ImmunGene, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Mar, 2014 19 pages
Binge Eating Disorder - Pipeline Review, H1 2014 US$ 2,000.00

... Review, H1 2014’, provides an overview of the Binge Eating Disorder’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for ... (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the ...

Mar, 2014 56 pages
Apceth GmbH & Co. KG - Product Pipeline Review - 2014 US$ 1,500.00

... description, key information and facts, and its locations and subsidiaries The report reviews current pipeline of Apceth GmbH & Co. KG’s human therapeutic ... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Apceth GmbH & Co. KG’s pipeline products ...

Mar, 2014 21 pages
Advanced Accelerator Applications - Product Pipeline Review - 2014 US$ 1,500.00

... action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Advanced Accelerator Applications’s pipeline products Reasons ...

Mar, 2014 21 pages
Thesan Pharmaceuticals, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Thesan Pharmaceuticals, Inc.’s pipeline products Reasons ... Assess the growth potential of Thesan Pharmaceuticals, Inc. in its therapy areas of focus Identify new drug targets and therapeutic classes in the ...

Feb, 2014 18 pages
LFB S.A. - Product Pipeline Review - 2014 US$ 1,500.00

... Summary Global Markets Direct’s, ‘LFB S.A. - Product Pipeline Review - 2014’, provides an overview of the LFB S.A.’s pharmaceutical research and development focus. This ... reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global ...

Feb, 2014 25 pages
Invion Limited - Product Pipeline Review - 2014 US$ 1,500.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Invion Limited’s pipeline products ... drug targets and therapeutic classes in the Invion Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Feb, 2014 32 pages
Dompe Farmaceutici S.p.A. - Product Pipeline Review - 2014 US$ 1,500.00

... The report reviews current pipeline of Dompe Farmaceutici S.p.A.’s human therapeutic division and enlists all their major and minor projects The report ... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Dompe Farmaceutici S.p.A.’s pipeline products ...

Feb, 2014 30 pages
Biota Pharmaceuticals, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... , key information and facts, and its locations and subsidiaries The report reviews current pipeline of Biota Pharmaceuticals, Inc.’s human therapeutic ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Biota Pharmaceuticals, Inc.’s pipeline products Reasons ...

Feb, 2014 45 pages
Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H1 2014 US$ 2,000.00

... , and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Juvenile Idiopathic Arthritis (SJIA). Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, Half Year is built using data and information sourced from ...

Jan, 2014 67 pages
Starpharma Holdings Limited - Product Pipeline Review - 2014 US$ 1,500.00

... milestones. Recent updates of the Starpharma Holdings Limited’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and ... . Assess the growth potential of Starpharma Holdings Limited in its therapy areas of focus. Identify new drug targets and therapeutic classes in the ...

Jan, 2014 27 pages
Primary Dysmenorrhea - Pipeline Review, H1 2014 US$ 2,000.00

... , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Primary Dysmenorrhea. Primary Dysmenorrhea - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s ...

Jan, 2014 39 pages
Nordmark Arzneimittel GmbH & Co. KG - Product Pipeline Review - 2014 US$ 1,500.00

... , complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from ... milestones. Recent updates of the Nordmark Arzneimittel GmbH & Co. KG’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and ...

Jan, 2014 29 pages
Motif BioSciences, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... , key information and facts, and its locations and subsidiaries. Review of current pipeline of Motif BioSciences, Inc. human therapeutic division. Overview ... milestones. Recent updates of the Motif BioSciences, Inc.’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and ...

Jan, 2014 23 pages
Batten Disease - Pipeline Review, H1 2014 US$ 2,000.00

... and discontinued projects. It also reviews key players involved in the therapeutic development for Batten Disease. Batten Disease - Pipeline Review, Half Year ... news and deals relating to the products. Reasons to buy Identify and understand important and diverse types of therapeutics under development for ...

Jan, 2014 44 pages
AmpliPhi Biosciences Corporation - Product Pipeline Review - 2014 US$ 1,500.00

... stages of drug development, including the combination treatment modalities, across the globe. Product profiles for late stage and clinical stage ... milestones. Recent updates of the AmpliPhi Biosciences Corporation’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and ...

Jan, 2014 35 pages
Vichem Chemie Research Ltd. - Product Pipeline Review - 2013 US$ 1,500.00

... featured press releases, both from Vichem Chemie Research Ltd. and industry-specific third party sources, put together by Global Markets ... pipeline of Vichem Chemie Research Ltd. human therapeutic division. Overview of pipeline therapeutics across various therapy areas. Coverage of current pipeline molecules ...

Dec, 2013 50 pages
Zambon Company S.p.A. - Product Pipeline Review - 2013 US$ 1,500.00

... history, mechanism of action, therapeutic class, target and major milestones. Recent updates of the Zambon Company S.p.A.’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and deals relating to the products. Reasons to buy Evaluate ...

Dec, 2013 43 pages
XTL Biopharmaceuticals Ltd. - Product Pipeline Review - 2013 US$ 1,500.00

... milestones. Recent updates of the XTL Biopharmaceuticals Ltd.’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and ... . Assess the growth potential of XTL Biopharmaceuticals Ltd. in its therapy areas of focus. Identify new drug targets and therapeutic classes in the ...

Dec, 2013 31 pages
Vitae Pharmaceuticals, Inc. - Product Pipeline Review - 2013 US$ 1,500.00

... milestones. Recent updates of the Vitae Pharmaceuticals, Inc.’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and ... . Assess the growth potential of Vitae Pharmaceuticals, Inc. in its therapy areas of focus. Identify new drug targets and therapeutic classes in the ...

Dec, 2013 38 pages
Ventria Bioscience - Product Pipeline Review - 2013 US$ 1,500.00

... ’s developmental history, mechanism of action, therapeutic class, target and major milestones. Recent updates of the Ventria Bioscience’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and deals relating to the products. Reasons to buy ...

Dec, 2013 30 pages
Vasomotor Symptoms of Menopause - Pipeline Review, H2 2013 US$ 2,000.00

... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vasomotor Symptoms of Menopause. Vasomotor Symptoms of Menopause - Pipeline Review, Half Year is built using data and information sourced from Global ...

Dec, 2013 51 pages
Valentia Biopharma S.L. - Product Pipeline Review - 2013 US$ 1,500.00

... of the Valentia Biopharma S.L.’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and deals relating to the products ... . Assess the growth potential of Valentia Biopharma S.L. in its therapy areas of focus. Identify new drug targets and therapeutic classes in the Valentia ...

Dec, 2013 21 pages
TWi Pharmaceuticals, Inc. - Product Pipeline Review - 2013 US$ 1,500.00

... major milestones. Recent updates of the TWi Pharmaceuticals, Inc.’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and ... . Assess the growth potential of TWi Pharmaceuticals, Inc. in its therapy areas of focus. Identify new drug targets and therapeutic classes in the ...

Dec, 2013 24 pages
Tularaemia - Pipeline Review, H2 2013 US$ 2,000.00

... and discontinued projects. It also reviews key players involved in the therapeutic development for Tularaemia. Tularaemia - Pipeline Review, Half Year is built ... news and deals relating to the products. Reasons to buy Identify and understand important and diverse types of therapeutics under development for ...

Dec, 2013 48 pages
Trophogen, Inc. - Product Pipeline Review - 2013 US$ 1,500.00

... description, key information and facts, and its locations and subsidiaries. Review of current pipeline of Trophogen, Inc. human therapeutic division. Overview of ... of the Trophogen, Inc.’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and deals relating to the products. ...

Dec, 2013 20 pages
Torii Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013 US$ 1,500.00

... molecules in various stages of drug development, including the combination treatment modalities, across the globe. Product profiles for late stage and ... milestones. Recent updates of the Torii Pharmaceutical Co., Ltd.’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and ...

Dec, 2013 33 pages
Tillotts Pharma AG - Product Pipeline Review - 2013 US$ 1,500.00

... business description, key information and facts, and its locations and subsidiaries. Review of current pipeline of Tillotts Pharma AG human therapeutic division ... of the Tillotts Pharma AG’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and deals relating to the products ...

Dec, 2013 25 pages
Tauopathies - Pipeline Review, H2 2013 US$ 2,000.00

... on the therapeutic development for Tauopathies, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tauopathies. Tauopathies - Pipeline Review, Half Year is built using data and ...

Dec, 2013 55 pages
Taiwan Liposome Company, Ltd. - Product Pipeline Review - 2013 US$ 1,500.00

... put together by Global Markets Direct’s team. Scope Taiwan Liposome Company, Ltd. - Brief Taiwan Liposome Company, Ltd. overview including business description ... . Recent updates of the Taiwan Liposome Company, Ltd.’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and ...

Dec, 2013 29 pages
TaiMed Biologics Inc. - Product Pipeline Review - 2013 US$ 1,500.00

... , key information and facts, and its locations and subsidiaries. Review of current pipeline of TaiMed Biologics Inc. human therapeutic division. Overview ... major milestones. Recent updates of the TaiMed Biologics Inc.’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and ...

Dec, 2013 31 pages
sterna biologicals Gmbh & Co KG - Product Pipeline Review - 2013 US$ 1,500.00

... press releases, both from sterna biologicals Gmbh & Co KG and industry-specific third party sources, put together by Global Markets Direct’s team. ... milestones. Recent updates of the sterna biologicals Gmbh & Co KG’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and ...

Dec, 2013 23 pages
Stemedica Cell Technologies, Inc. - Product Pipeline Review - 2013 US$ 1,500.00

... Cell Technologies, Inc. overview including business description, key information and facts, and its locations and subsidiaries. Review of current pipeline of ... . Recent updates of the Stemedica Cell Technologies, Inc.’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and ...

Dec, 2013 27 pages
Spring Bank Pharmaceuticals, Inc. - Product Pipeline Review - 2013 US$ 1,500.00

... Bank Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries. Review of current pipeline ... . Recent updates of the Spring Bank Pharmaceuticals, Inc.’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and ...

Dec, 2013 23 pages
Soricimed Biopharma Inc. - Product Pipeline Review - 2013 US$ 1,500.00

... , key information and facts, and its locations and subsidiaries. Review of current pipeline of Soricimed Biopharma Inc. human therapeutic division. Overview ... milestones. Recent updates of the Soricimed Biopharma Inc.’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and ...

Dec, 2013 24 pages
SK Chemicals Co., Ltd. - Product Pipeline Review - 2013 US$ 1,500.00

... molecules in various stages of drug development, including the combination treatment modalities, across the globe. Product profiles for late stage and ... milestones. Recent updates of the SK Chemicals Co., Ltd.’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and deals ...

Dec, 2013 45 pages
Serometrix, LLC - Product Pipeline Review - 2013 US$ 1,500.00

... description, key information and facts, and its locations and subsidiaries. Review of current pipeline of Serometrix, LLC human therapeutic division. Overview of ... of the Serometrix, LLC’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and deals relating to the products. ...

Dec, 2013 24 pages
Serodus ASA - Product Pipeline Review - 2014 US$ 1,500.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Serodus ASA’s pipeline products ... new drug targets and therapeutic classes in the Serodus ASA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Feb, 2014 28 pages
Selvita S.A - Product Pipeline Review - 2013 US$ 1,500.00

... report, “Selvita S.A - Product Pipeline Review - 2013” provides data on the Selvita S.A’s research and development focus. The report includes information on current ... , complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from ...

Dec, 2013 34 pages
Sanwa Kagaku Kenkyusho Co., Ltd. - Product Pipeline Review - 2013 US$ 1,500.00

... Direct’s team. Scope Sanwa Kagaku Kenkyusho Co., Ltd. - Brief Sanwa Kagaku Kenkyusho Co., Ltd. overview including business description, key information and ... . Recent updates of the Sanwa Kagaku Kenkyusho Co., Ltd.’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and ...

Dec, 2013 33 pages
Rubella - Pipeline Review, H2 2013 US$ 2,000.00

... and discontinued projects. It also reviews key players involved in the therapeutic development for Rubella. Rubella - Pipeline Review, Half Year is built ... important and diverse types of therapeutics under development for Rubella. Identify emerging players with potentially strong product portfolio and design ...

Dec, 2013 38 pages
Rhizen Pharmaceuticals SA - Product Pipeline Review - 2013 US$ 1,500.00

... pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from ... of the Rhizen Pharmaceuticals SA’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and deals relating to the products. ...

Dec, 2013 31 pages
Retrophin, LLC - Product Pipeline Review - 2013 US$ 1,500.00

... description, key information and facts, and its locations and subsidiaries. Review of current pipeline of Retrophin, LLC human therapeutic division. Overview of ... of the Retrophin, LLC’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and deals relating to the products. ...

Dec, 2013 26 pages
reMYND - Product Pipeline Review - 2013 US$ 1,500.00

... report, “reMYND - Product Pipeline Review - 2013” provides data on the reMYND’s research and development focus. The report includes information on current ... and major milestones. Recent updates of the reMYND’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and deals ...

Dec, 2013 26 pages
Relevare Pharmaceuticals Ltd. - Product Pipeline Review - 2013 US$ 1,500.00

... molecules in various stages of drug development, including the combination treatment modalities, across the globe. Product profiles for late stage and ... milestones. Recent updates of the Relevare Pharmaceuticals Ltd.’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and ...

Dec, 2013 28 pages
1 2 3 4 5 >
Skip to top